Elsevier Inc.

SHERPA: Unknown

People

  1. Lesokhin
    Lesokhin
  2. Hassoun
    Hassoun
  3. Giralt
    Giralt
  4. Landau
    Landau
  5. Mailankody
    Mailankody
  6. Korde
    Korde
  7. Shah
    Shah
  8. Hultcrantz
    Hultcrantz
  9. Usmani
    Usmani
  10. Shah
    Shah

Groups

  1. Center for Hematologic Malignancies (159)
  2. Department of Medicine (159)
  3. Hematologic Malignancies, Division of (159)
  4. Myeloma (159)
  5. Hematologic Malignancies Research (110)
  6. Survivorship Research (90)
  7. Bone Marrow Transplant (78)
  8. Sloan Kettering Institute Postdocs (58)
  9. CTCR Scholars (53)
  10. Epidemiology and Biostatistics (46)
Search Within
  1. "Myeloma"
Formats
  1. Meeting Abstract (114)
  2. Journal Article (27)
  3. Review (13)
  4. Book Section (1)
  5. Conference Paper (1)
  6. Editorial (1)
  7. Guidelines (1)
  8. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (159)
  2. Department of Medicine (159)
  3. Hematologic Malignancies, Division of (159)
  4. Myeloma (159)
  5. Hematologic Malignancies Research (110)
  6. Survivorship Research (90)

More Groups

People
  1. Alexander Lesokhin (78)
  2. Hani Hassoun (73)
  3. Heather Landau (70)
  4. Sergio Giralt (70)
  5. Sham Mailankody (70)
  6. David Chung (62)

More People

Years
  1. 2025 (1)
  2. 2024 (20)
  3. 2023 (31)
  4. 2022 (19)
  5. 2021 (10)
  6. 2020 (22)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (96)
  2. Biology of Blood and Marrow Transplantation (29)
  3. Best Practice and Research: Clinical Haematology (9)
  4. Seminars in Oncology (7)
  5. Transplantation and Cellular Therapy (4)
  6. International Journal of Radiation Oncology, Biology, Physics (3)

More Publications

Results (159)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Addition of elotuzumab to backbone treatment regimens for multiple myeloma: An updated meta-analysis of randomized clinical trials
    Journal Article

    Costa, B. A.; Costa, T. A.; Chagas, G. C. L.; Mouhieddine, T. H.; Richter, J.; Usmani, S. Z.; Mailankody, S.; Rajeeve, S.; Hashmi, H.
    Clinical Lymphoma, Myeloma and Leukemia (2025)

    Fulltext@MSK | Save
  • Early experience with salvage RT for relapsed / refractory multiple myeloma following BCMA-directed CART cell therapy
    Meeting Abstract

    Dreyfuss, A.; Fregonese, B.; Mailankody, S.; Usmani, S.; Imber, B. S.; Yahalom, J.
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Failure patterns by PET for relapsed / refractory Multiple Myeloma (r/r MM) after CART cell therapy: Potential role for radiotherapy (RT)?
    Meeting Abstract

    Dreyfuss, A.; Fregonese, B.; Hubbeling, H. G.; Mailankody, S.; Usmani, S.; Yahalom, J.; Imber, B. S.
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Characteristics of patients and management of ocular adverse events after treatment with belantamab mafodotin (belamaf) in relapsed/refractory multiple myeloma (RRMM): A real-world study in Europe
    Meeting Abstract

    Cavo, M.; Delforge, M.; Dimopoulos, M.; Escalante-Barrigon, F.; Hultcrantz, M.; Kleinman, D.; Lee, H.; Vij, R.; Greil, R.; Melchardt, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • MagnetisMM-30: A phase 1B, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)
    Meeting Abstract

    Lesokhin, A.; Raza, M.; Acosta, J.; Mueller, P. Y.; O'Connell, A.; Yver, A.; Lou, C.; Finn, G.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Whole genome sequencing reveals lower APOBEC-mutational activity in multiple myeloma patients with African ancestry compared with those of non-African ancestry
    Meeting Abstract

    Maclachlan, K.; Papadimitriou, M.; Blaney, P.; McPherson, A.; Chu, T.; Diamond, B.; Ziccheddu, B.; Shekarkhand, T.; Poos, A.; Brown, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Rajeeve, S.; Hashmi, H.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save